Basic and Clinical Research Programs |
|
Welcome to our Basic and Clinical Research Programs Newsletter.
The goal in creating this newsletter is to keep our members informed and involved. We are highlighting opportunities for collaborations, new funding opportunities, new grants and promotions, new members, along with past and upcoming seminars and events.
We always welcome your suggestions and contributions for future issues. Past issues of the Basic and Clinical Research Programs Newsletter can be found online here at the Rutgers Cancer Institute's website.
|
|
Dear Program Members,
As we approach the end of 2021, I want to recognize the outstanding efforts of the Research Program Leaders and Members to promote scientific engagement and progress while COVID-19 continued to inhibit in-person activities and travel. Important scientific meetings occurred virtually, PIs obtained peer-reviewed funding and publications, new Members joined the Research Programs, and key partnerships within the Consortium were established or enhanced. Further information on all of these achievements can be found later on in this newsletter. While we must remain vigilant to promote safety as new COVID-19 variants emerge, I am hopeful that 2022 will bring a return to a “new normal” for the faculty and trainees. We can already look forward to the next Rutgers Cancer Institute-Princeton University Annual Cancer Research Symposium occurring in early January, and every effort will be made to again hold the Annual Retreat on Cancer Research in New Jersey this Spring.
I wish you all a Happy and Healthy Holiday Season.
Sincerely,
Eileen White, PhD
Deputy Director, Chief Scientific Officer, and Associate Director for Basic Research
Rutgers Cancer Institute of New Jersey
|
|
2021 RBHS Chancellor Awards |
|
The RBHS Chancellor’s office is pleased to announce the recipients of the second annual RBHS Chancellor Awards. The RBHS Chancellor Awards were established to acknowledge the extraordinary work of our faculty and staff.
Please join us in congratulating our honored members:
Distinguished Mentor Award
For being a dedicated, selfless, and effective teacher, advocate, and mentor to scores of high school, undergraduate and graduate students, postgraduate trainees, and new faculty throughout her career.
Basic Sciences Researcher Award
Established Investigators
For his pioneering work on DNA damage and for building a world class radiation cancer biology program at Rutgers.
|
|
2021 Virtual Program Meetings |
|
Upcoming CMG Program Meetings:
Past CMG Program Meetings:
|
|
Upcoming CP Program Meetings:
Past CP Program Meetings:
|
|
Upcoming CIPT Program Meetings:
Past CIPT Program Meetings:
|
|
Upcoming GICG Program Meetings:
1/12/22 @12:00pm: Canceled
Past GICG Program Meetings:
|
|
Interested in being a speaker at a Research Program Meeting? Contact the Program Leader:
Cancer Metabolism & Growth (CMG)
Cancer Pharmacology (CP)
Clinical Investigations & Precision Therapeutics (CIPT)
Genomic Instability & Cancer Genetics (GICG)
|
|
NEW CANCER CENTER SUPPORT GRANT (CCSG) SUBPROJECT NUMBERS |
|
NCI has assigned a unique subproject number for each CCSG component. When acknowledging the CCSG in publications that resulted from Pilot Award/New Investigator funds and/or use of any supported Shared Resources - please use all of the appropriate CCSG grant numbers from the following:
|
|
*Pilot Awards and New Investigator Awards |
|
Rutgers Cancer Institute-Princeton University
Annual Cancer Research Symposium
|
|
SAVE THE DATE
JANUARY 11, 2022
9:00 AM-5:00 PM
Please join us for the second annual cancer research symposium jointly sponsored by Rutgers Cancer Institute of New Jersey and Princeton University. The goal of this symposium is to facilitate inter-institutional collaborations between researchers.
Agenda includes faculty presentations, trainee talks, and posters selected from submitted abstracts. Featured sessions focus on Cancer Genomics, Cancer Metabolism and Tumor Microenvironment, Understanding and Addressing Cancer Burden in the Population.
Looking forward to virtually seeing everyone!
|
|
Annual Retreat on Cancer Research |
|
SAVE THE DATE
May 25, 2022
Each year, Rutgers Cancer Institute of New Jersey and the New Jersey Commission on Cancer Research (NJCCR) host the Annual Retreat on Cancer Research in New Jersey, a gathering of world-renowned scientists from the cancer field. The event includes a series of simultaneous mini-symposia as well as several poster sessions highlighting the latest cancer research being conducted at the Cancer Institute and other leading institutions throughout New Jersey. The event also includes a public forum focused on advances in cancer research and treatment in the past year. A panel of expert researchers from New Jersey present perspectives on the following subjects: nutrition and cancer prevention, angiogenesis, emerging new drugs for therapy, genetics of cancer, and complementary medicine. There is no cost to attend the Annual Retreat on Cancer Research in New Jersey but registration is a must.
|
|
CINJ recruits leading statistician to direct the Biostatistics Shared Resource!
Hao Liu, PhD, joined Rutgers as a Professor of Biostatistics to lead the Biostatistics (formerly Biometrics) Shared Resource at Rutgers Cancer Institute. Dr. Liu earned a PhD. in Biostatistics from the University of Washington and a master’s degree in Biostatistics from the University of California at Berkeley. Before joining Rutgers University, he was a Professor of Biostatistics and the Director of the Biostatistics and Data Management Core at Indiana University Simon Comprehensive Cancer Center.
Dr. Liu has over 15 years of experience in providing biostatistics support in cancer research and has regularly collaborated with basic science investigators with experimental design, data analysis and statistical methodology development. His research interests have been primarily focused on the analysis of complex data, development of novel statistical trial designs for personalized medicine, and new statistical machine learning methods for massive data. His vision for Biostatistics is to bring about the state-of-the-art statistical methods and data analysis techniques to meet the research needs at the Rutgers Cancer Institute in the rapidly changing landscape of cancer drug development, precision medicine as well as the brave new world of AI and machine learning for analyzing big omics data and massive EHR data that could profoundly benefit research, clinical care, and cancer prevention.
Dr. Liu will be presenting his research, discussing the Shared Resource’s capabilities, and reaching out to members during upcoming meetings of all 5 research programs.
|
|
Ludwig Institute for Cancer Research Launches Newest Branch at Princeton University in Partnership with Rutgers Cancer Institute of New Jersey and RWJBarnabas Health |
|
Ludwig Institute for Cancer Research, established since 1971 as an international, not-for-profit organization, launched its newest branch at Princeton University in April 2021. The Ludwig Princeton Branch is affiliated with RWJBarnabas Health and Rutgers Cancer Institute of New Jersey. Drawing on ample research strengths of the partner institutions, the branch is dedicated to the study of cancer metabolism and the development of novel metabolic interventions for the prevention, diagnosis, and treatment of cancer.
The Ludwig Princeton Branch will focus on three main areas of cancer metabolism: metabolic interactions between the tumor and the rest of the body; the influence of diet on the prevention and treatment of cancer; and the connection of host metabolism, the gut microbiome and the anti-cancer immune response. “We look forward to the discoveries made through this new collaboration, which will be translated into clinical trials available through RWJBarnabas Health, Rutgers Cancer Institute and beyond,” said Rutgers Cancer Institute Director Steven Libutti, MD, FACS.
The branch has three founding members. It is directed by Joshua Rabinowitz, MD, PhD, a Professor in the Department of Chemistry and the Lewis-Sigler Institute for Integrative Genomics at Princeton University. He is also the Director of the Metabolomics Shared Resource at Rutgers Cancer Institute. Rabinowitz has made seminal contributions to the field of metabolomics—the large-scale, quantitative analysis of metabolites—and cancer metabolism. Two other members are Associate Director Eileen White, PhD, a member of the National Academy of Sciences who is also Distinguished Professor of Molecular Biology and Biochemistry at Rutgers University, Rutgers Cancer Institute’s Deputy Director and Chief Scientific Officer, and Yibin Kang, PhD, the Warner-Lambert/Parke-Davis Professor of Molecular Biology at Princeton University and Associate Director for Consortium Research at Rutgers Cancer Institute.
The Ludwig Princeton Branch is in the process of recruiting faculty members at all levels as well as postdoctoral associates to join in its research mission. To learn more, please see the following links:
|
|
Program Liaisons Play an Integrative Role in Bridging CINJ Research and New Jersey Cancer Intervention Priorities |
|
Due to their high prevalence or mortality rates in New Jersey, lung, prostate, breast, colorectal, melanoma, and cervical cancers are top priority cancers that demand exceptional care for reducing the cancer burden in our state. There also are significant disparities in cancer incidence and mortality rates in the state. To fulfill its research and patient care mission in serving populations in its catchment area and beyond, Rutgers Cancer Institute of New Jersey (CINJ), the only NCI-designated Comprehensive Cancer Center in NJ, has a robust comprehensive Community Outreach and Engagement (COE) program to monitor the cancer burden and disparities, to facilitate community engagement in cancer intervention and research efforts, and to catalyze catchment area-relevant research. Within the COE’s framework, a highly talented team of program liaisons plays an active role in bridging CINJ research efforts with the needs as well as engagement of community shareholders in NJ.
Current program liaison members comprise six investigators across the five research programs in CINJ:
The Program liaisons are active investigators in their respective field. They facilitate multi-level communication between the voices of community shareholders (e.g., patient advocates, organizations, and providers), COE outreach activities and findings on catchment area cancer burden and need, and catchment area-relevant research projects and findings of CINJ researchers (program leaders, members, and trainees) and their need for community engagement (e.g., participant recruitment and biospecimen acquisition). There is no doubt that such bi- or multi-directional communication is beneficial to both the community members and researchers. As a result, each of the five programs has an expanding number of studies addressing major cancer burdens in NJ. For instance, the investigators in the GICG program are conducting research that targets autophagy in hereditary cancer (Dr. White), or BRG1-SOX4 signaling in triple negative breast cancer (Dr. Gatza), or molecular determinants of lung cancer health disparities (Dr. Pine).
Given the increasingly important role of the program liaisons in bidirectional community-cancer researcher engagement, it is anticipated that the liaisons will continue to make a significant contribution to CINJ’s mission. According to Anita Kinney, who oversees the catchment area and COE activities of CINJ, part of the future plans of the COE is to further maximize the integration of program liaisons to catalyze CINJ’s catchment area research.
|
|
Welcoming
Haejin In, MD, MPH, MBA, FACS, FSSO
|
|
Haejin In, MD joins Rutgers Cancer Institute of New Jersey as the Associate Director for Diversity, Equity, and Inclusion and will serve as a change agent, consultant, and thought-leader on diversity and inclusion related issues that impact faculty, staff, and leadership. In this role, Dr. In will lead strategic initiatives that institutionalize these important topics and align and increase diversity and inclusion goals.
Prior to joining Rutgers Cancer Institute, Dr. In was at Albert Einstein College of Medicine where she was an Associate Professor of Surgery and Epidemiology and Population Health, and also held the position of Director, Surgical Resident Research at Montefiore Medical Center.
In addition to her role as an Associate Director, Dr. In is a Surgical Oncologist and an Associate Professor of Surgery at Robert Wood Johnson Medical School, with an expertise in GI-related cancers.
|
|
Cancer Metabolism & Growth |
|
Alexander Ploss, PhD was awarded a NJ ACTS grant entitled "Characterizing the Impact of SARS-CoV-2 Genome Evolution on Human Pulmonary Responses". Term: 09/01/2021 - 08/33/2022. Total Annual Costs: $50,000.
Alexander Ploss, PhD was awarded a Princeton Catalysis Initiative grant entitled "Profiling the RNA Modification Landscape of SARS-CoV-2". Term: 07/01/2021 - 06/30/2022. Total Annual Costs: $60,000.
Alexander Valvezan, PhD was awarded the Leukemia Research Foundation Research Grant, entitled "Repurposing IMPDH inhibitors for selective targeting of PTEN-deficient T-ALL cells". Term: 07/01/2021 - 06/30/2022. Total Annual Costs: $100,000.
Christian Hinrichs, MD was awarded a Neogene Therapeutics, Inc. grant entitled "Neogene Clinical Research Agreement". Term: 08/16/2021 - 03/01/2023. Total Annual Costs: $895,440.
Debra Laskin, PhD was awarded with the Distinguished Mentor Award presented by the RBHS Chancellor Awards in November 2021.
Harini Sampath, PhD was awarded a NIDDK grant entitled "The Role of Intestinal SCD1 in Regulating Metabolic Health". Grant Number: 1R01DK126963-01A1. Term: 07/01/2021 - 06/30/2026. Total Annual Costs: $391,632.
Joshua D. Rabinowitz, MD, PhD was awarded a Princeton Catalysis Initiative grant entitled "Cracking the Localization Code: Addressing Small Molecules to Specific Tissues and Organellest". Term: 07/01/2021 - 06/30/2022. Total Annual Costs: $60,000.
M. Maral Mouradian, MD was awarded a NINDS grant entitled "Role of Transglutaminase 2 in Synucleinopathies". Grant Number: 1R21NS123770-01. Term: 07/01/2021 - 12/31/2022. Total Annual Costs: $431,750.
M. Maral Mouradian, MD was awarded a NINDS grant entitled "Training in Translating Neuroscience to Therapies". Grant Number: 1T32NS115700-01A1. Term: 07/01/2021 - 06/30/2026. Total Annual Costs: $197,967.
Yibin Kang, PhD was awarded a Breast Cancer Research Foundation grant entitled "The Role of Metadherin in Immune Evasion of Metastatic Breast Cancer". Term: 10/01/2021 - 09/30/2022. Total Annual Costs: $190,000.
Zemer Gitai, PhD was awarded a NCCIH grant entitled "Small RNAs as Novel Modulators of Microbehost Interactions". Grant Number: 1R01AT011963-01. Term: 09/01/2021 - 04/30/2026. Total Annual Costs: $1,505,179.
|
|
Eileen White, PhD presented “How to promote women in science” and “Role of autophagy in regulating the anti-cancer immune response” at the Frankfurt Cancer Conference held August 24-26, 2021 virtually.
Eileen White, PhD presented “Role of Autophagy in cancer metabolism and Immune tolerance” at the Swiss Institute for Experimental Cancer Research (ISREC)- Swiss Cancer Center Leman (SCCL) Symposia - "Hallmarks of Cancer - 20 Years On" held August 28-31, 2021 at SwissTech Convention Center in Lausanne, Switzerland.
Eileen White, PhD presented “Metabolic and Immune Regulation of Cancer” at the University of Virginia Cancer Center’s Michael J. Weber Symposium held October 15, 2021 virtually.
Eileen White, PhD presented "Metabolic Regulation of the Anti-Cancer Immune Response" at MD Anderson Cancer Center’s Blaffer Virtual Lecture Series held October 19, 2021 virtually.
|
|
Bartman CR, TeSlaa T, Rabinowitz JD. Quantitative flux analysis in mammals. Nat Metab. 2021;3(7):896-908. Epub 2021/07/03. doi: 10.1038/s42255-021-00419-2. PubMed PMID: 34211182.
Cable J, Pourquie O, Wellen KE, Finley LWS, Aulehla A, Gould AP, Teleman A, Tu WB, Garrett WS, Miguel-Aliaga I, Perrimon N, Hooper LV, Walhout AJM, Wei W, Alexandrov T, Erez A, Ralser M, Rabinowitz JD, Hemalatha A, Gutierrez-Perez P, Chandel NS, Rutter J, Locasale JW, Landoni JC, Christofk H. Metabolic decisions in development and disease-a Keystone Symposia report. Ann N Y Acad Sci. 2021. Epub 2021/08/21. doi: 10.1111/nyas.14678. PubMed PMID: 34414571.
Calianese D, Kreiss T, Kasikara C, Davra V, Lahey KC, Gadiyar V, Geng K, Singh S, Honnen W, Jaijyan DK, Reichman C, Siekierka J, Gennaro ML, Kotenko SV, Ucker DS, Brekken RA, Pinter A, Birge RB, Choudhary A. Phosphatidylserine-Targeting Monoclonal Antibodies Exhibit Distinct Biochemical and Cellular Effects on Anti-CD3/CD28-Stimulated T Cell IFN-gamma and TNF-alpha Production. J Immunol. 2021;207(2):436-48. Epub 2021/07/04. doi: 10.4049/jimmunol.2000763. PubMed PMID: 34215655.
Garcia-Canaveras JC, Heo D, Trefely S, Leferovich J, Xu C, Philipson BI, Ghassemi S, Milone MC, Moon EK, Snyder NW, June CH, Rabinowitz JD, O'Connor RS. CAR T-Cells Depend on the Coupling of NADH Oxidation with ATP Production. Cells. 2021;10(9). Epub 2021/09/29. doi: 10.3390/cells10092334. PubMed PMID: 34571983; PMCID: PMC8472053.
Goswami S, Balasubramanian I, D'Agostino L, Bandyopadhyay S, Patel R, Avasthi S, Yu S, Goldenring JR, Bonder EM, Gao N. RAB11A-mediated YAP localization to adherens and tight junctions is essential for colonic epithelial integrity. J Biol Chem. 2021;297(1):100848. Epub 2021/06/01. doi: 10.1016/j.jbc.2021.100848. PubMed PMID: 34058200; PMCID: PMC8254046.
Jariwala N, Mehta GA, Bhatt V, Hussein S, Parker KA, Yunus N, Parker JS, Guo JY, Gatza ML. CPT1A and fatty acid beta-oxidation are essential for tumor cell growth and survival in hormone receptor-positive breast cancer. NAR Cancer. 2021;3(3):zcab035. Epub 2021/09/14. doi: 10.1093/narcan/zcab035. PubMed PMID: 34514415; PMCID: PMC8428294.
Klionsky DJ, Petroni G, Amaravadi RK, Baehrecke EH, Ballabio A, Boya P, Bravo-San Pedro JM, Cadwell K, Cecconi F, Choi AMK, Choi ME, Chu CT, Codogno P, Colombo MI, Cuervo AM, Deretic V, Dikic I, Elazar Z, Eskelinen EL, Fimia GM, Gewirtz DA, Green DR, Hansen M, Jaattela M, Johansen T, Juhasz G, Karantza V, Kraft C, Kroemer G, Ktistakis NT, Kumar S, Lopez-Otin C, Macleod KF, Madeo F, Martinez J, Melendez A, Mizushima N, Munz C, Penninger JM, Perera RM, Piacentini M, Reggiori F, Rubinsztein DC, Ryan KM, Sadoshima J, Santambrogio L, Scorrano L, Simon HU, Simon AK, Simonsen A, Stolz A, Tavernarakis N, Tooze SA, Yoshimori T, Yuan J, Yue Z, Zhong Q, Galluzzi L, Pietrocola F. Autophagy in major human diseases. EMBO J. 2021;40(19):e108863. Epub 2021/08/31. doi: 10.15252/embj.2021108863. PubMed PMID: 34459017; PMCID: PMC8488577.
Lee E, Kang Y. Lineage tracing reveals metastatic dynamics. Cancer Cell. 2021;39(8):1050-2. Epub 2021/06/26. doi: 10.1016/j.ccell.2021.06.005. PubMed PMID: 34171265.
Malaviya R, Bellomo A, Abramova E, Croutch CR, Roseman J, Tuttle R, Peters E, Casillas RP, Sunil VR, Laskin JD, Laskin DL. Pulmonary injury and oxidative stress in rats induced by inhaled sulfur mustard is ameliorated by anti-tumor necrosis factor-alpha antibody. Toxicol Appl Pharmacol. 2021;428:115677. Epub 2021/08/15. doi: 10.1016/j.taap.2021.115677. PubMed PMID: 34390737; PMCID: PMC8452183.
Poillet-Perez L, White E. MDVs to the rescue: How autophagy-deficient cancer cells adapt to defective mitophagy. Dev Cell. 2021;56(14):2010-2. Epub 2021/07/28. doi: 10.1016/j.devcel.2021.06.022. PubMed PMID: 34314695.
Rabie EM, Zhang SX, Dunn CE, Nelson CM. Substratum stiffness signals through integrin-linked kinase and beta1-integrin to regulate midbody proteins and abscission during EMT. Mol Biol Cell. 2021;32(18):1664-76. Epub 2021/05/27. doi: 10.1091/mbc.E21-02-0072. PubMed PMID: 34038147.
Rangel M, Kong J, Bhatt V, Khayati K, Guo JY. Autophagy and tumorigenesis. FEBS J. 2021. Epub 2021/07/17. doi: 10.1111/febs.16125. PubMed PMID: 34270851.
Robbins Y, Friedman J, Clavijo PE, Sievers C, Bai K, Donahue RN, Schlom J, Sinkoe A, Hinrichs CS, Allen C, Abdul Sater H, Gulley JL, Norberg S. Dual PD-L1 and TGF-b blockade in patients with recurrent respiratory papillomatosis. J Immunother Cancer. 2021;9(8). Epub 2021/09/01. doi: 10.1136/jitc-2021-003113. PubMed PMID: 34462327; PMCID: PMC8407210.
Sciarretta S, Schirone L, Sadoshima J. Editorial commentary: How to implement research studies on extracellular vesicle administration in myocardial infarction. Trends Cardiovasc Med. 2021;31(7):416-8. Epub 2020/09/26. doi: 10.1016/j.tcm.2020.09.003. PubMed PMID: 32976978.
Sherman LS, Patel SA, Castillo MD, Unkovic R, Taborga M, Gergues M, Patterson S, Etchegaray JP, Jaloudi M, Hooda-Nehra A, Kra J, Rojas DP, Chang VT, Rameshwar P. NFkB Targeting in Bone Marrow Mesenchymal Stem Cell-Mediated Support of Age-Linked Hematological Malignancies. Stem Cell Rev Rep. 2021;17(6):2178-92. Epub 2021/08/20. doi: 10.1007/s12015-021-10235-6. PubMed PMID: 34410592.
Shim G, Devenport D, Cohen DJ. Overriding native cell coordination enhances external programming of collective cell migration. Proc Natl Acad Sci U S A. 2021;118(29). Epub 2021/07/18. doi: 10.1073/pnas.2101352118. PubMed PMID: 34272284; PMCID: PMC8307614.
Silver BB, Zhang SX, Rabie EM, Nelson CM. Substratum stiffness tunes membrane voltage in mammary epithelial cells. J Cell Sci. 2021;134(13). Epub 2021/07/28. doi: 10.1242/jcs.256313. PubMed PMID: 34313313; PMCID: PMC8310660.
Szwed A, Kim E, Jacinto E. Regulation and metabolic functions of mTORC1 and mTORC2. Physiol Rev. 2021;101(3):1371-426. Epub 2021/02/19. doi: 10.1152/physrev.00026.2020. PubMed PMID: 33599151; PMCID: PMC8424549.
White E, Lattime EC, Guo JY. Autophagy Regulates Stress Responses, Metabolism, and Anticancer Immunity. Trends Cancer. 2021;7(8):778-89. Epub 2021/06/12. doi: 10.1016/j.trecan.2021.05.003. PubMed PMID: 34112622; PMCID: PMC8295230.
Yang CS, Chen XL. Research on esophageal cancer: With personal perspectives from studies in China and Kenya. Int J Cancer. 2021;149(2):264-76. Epub 2020/12/04. doi: 10.1002/ijc.33421. PubMed PMID: 33270917; PMCID: PMC8141013.
Zhang M, Zhao Z, Pritykin Y, Hannum M, Scott AC, Kuo F, Sanghvi V, Chan TA, Seshan V, Wendel HG, Schietinger A, Sadelain M, Huse M. Ectopic activation of the miR-200c-EpCAM axis enhances antitumor T cell responses in models of adoptive cell therapy. Sci Transl Med. 2021;13(611):eabg4328. Epub 2021/09/16. doi: 10.1126/scitranslmed.abg4328. PubMed PMID: 34524864.
Zhang S, Zhou YF, Cao J, Burley SK, Wang HY, Zheng XFS. mTORC1 Promotes ARID1A Degradation and Oncogenic Chromatin Remodeling in Hepatocellular Carcinoma. Cancer Res. 2021;81(22):5652-65. Epub 2021/08/26. doi: 10.1158/0008-5472.CAN-21-0206. PubMed PMID: 34429326; PMCID: PMC8595749.
|
|
RBHS Chancellor Lifetime Achievement Award |
|
We are proud to announce that Joseph R. Bertino, M.D. is the inaugural and 2021 recipient of the Rutgers Biomedical and Health Sciences (RBHS) Chancellor Lifetime Achievement Award. This honor is bestowed posthumously in recognition of Dr. Bertino’s unmatched fundamental contributions to cancer research as a renowned scientist, inspirational mentor, cherished colleague, University Professor of Medicine and Pharmacology at Robert Wood Johnson Medical School, and former Chief Scientific Officer at Rutgers Cancer Institute of New Jersey.
|
|
Ann M. Stock, PhD was awarded a NSF grant entitled "Collaborative Research: Chemotactic Signaling in Sinorhizobium Meliloti Symbiotic Plant Host Interaction". Term: 08/01/2021 - 07/31/2023. Total Annual Costs: $98,645.
Daniel Herranz Benito, PhD was awarded an AACR grant entitled "A Novel Mitochondrial Uncoupling Drug in the Treatment of Leukemia". Term: 07/01/2021 - 06/30/2022. Total Annual Costs: $50,000.
Hong Li, PhD was awarded a Renalytix grant entitled "Multi-Center Assessment of Survivors for Kidney Disease After COVID-19". Term: 07/01/2021 - 06/30/2023. Total Annual Costs: $260,000.
Jason Kaelber, PhD was awarded a NIGMS grant entitled "Improving Cryoem and Cryofib Performance Through Amelioration of Mechanical Stress in Vitreous Ice". Grant Number: 1R21GM140345-01A1. Term: 09/01/2021 - 08/31/2023. Total Annual Costs: $235,500.
Mi-Hyeon Jang, PhD was awarded a NCI grant entitled "Targeting NAMPT-Mediated NAD+ Metabolism in Chemobrain (Research Supplements to Promote Diversity in Health-Related Research)". Grant Number: 3R01CA242158-04S1. Term: 08/08/2021 - 07/31/2024. Total Annual Costs: $116,447.
X. F. Steven Zheng, PhD was awarded a NCI grant entitled "Metabolic Control and Anticancer Mechanism". Grant Number: 1R01CA260006-01. Term: 07/01/2021 - 06/30/2026. Total Annual Costs: $341,161.
|
|
da Silva-Diz V, Cao B, Lancho O, Chiles E, Alasadi A, Aleksandrova M, Luo S, Singh A, Tao H, Augeri D, Minuzzo S, Indraccolo S, Khiabanian H, Su X, Jin S, Herranz D. A novel and highly effective mitochondrial uncoupling drug in T-cell leukemia. Blood. 2021;138(15):1317-30. Epub 2021/04/21. doi: 10.1182/blood.2020008955. PubMed PMID: 33876224; PMCID: PMC8525334.
Daquinag AC, Gao Z, Fussell C, Immaraj L, Pasqualini R, Arap W, Akimzhanov AM, Febbraio M, Kolonin
MG. Fatty acid mobilization from adipose tissue is mediated by CD36 posttranslational modifications and intracellular trafficking. JCI Insight. 2021;6(17). Epub 2021/07/28. doi: 10.1172/jci.insight.147057. PubMed PMID: 34314388; PMCID: PMC8492349.
Eddy K, Chen S. Glutamatergic Signaling a Therapeutic Vulnerability in Melanoma. Cancers (Basel). 2021;13(15). Epub 2021/08/08. doi: 10.3390/cancers13153874. PubMed PMID: 34359771; PMCID: PMC8345431.
Foo TK, Vincelli G, Huselid E, Her J, Zheng H, Simhadri S, Wang M, Huo Y, Li T, Yu X, Li H, Zhao W, Bunting SF, Xia B. ATR/ATM-Mediated Phosphorylation of BRCA1 T1394 Promotes Homologous Recombinational Repair and G2-M Checkpoint Maintenance. Cancer Res. 2021;81(18):4676-84. Epub 2021/07/25. doi: 10.1158/0008-5472.CAN-20-2723. PubMed PMID: 34301763; PMCID: PMC8448966.
Lee JB, Zang X, Zgair A, Ooi TQ, Foley DW, Voronin G, Kagan L, Soukarieh F, Gao R, Shao H, Soh WT, Kim TH, Kim MG, Yun HY, Wilson AJ, Fischer PM, Gershkovich P. Administration in fed state but not controlled release in the colon increases oral bioavailability of DF030263, a promising drug candidate for chronic lymphocytic leukemia. Eur J Pharm Biopharm. 2021;165:106-12. Epub 2021/05/16. doi: 10.1016/j.ejpb.2021.05.006. PubMed PMID: 33991611.
Majumder J, Minko T. Multifunctional Lipid-Based Nanoparticles for Codelivery of Anticancer Drugs and siRNA for Treatment of Non-Small Cell Lung Cancer with Different Level of Resistance and EGFR Mutations. Pharmaceutics. 2021;13(7). Epub 2021/08/11. doi: 10.3390/pharmaceutics13071063. PubMed PMID: 34371754; PMCID: PMC8309189.
Murari A, Rhooms SK, Garcia C, Liu T, Li H, Mishra B, Deshong C, Owusu-Ansah E. Dissecting the concordant and disparate roles of NDUFAF3 and NDUFAF4 in mitochondrial complex I biogenesis. iScience. 2021;24(8):102869. Epub 2021/08/14. doi: 10.1016/j.isci.2021.102869. PubMed PMID: 34386730; PMCID: PMC8346666.
Nomani A, Li G, Yousefi S, Wu S, Malekshah OM, Nikkhoi SK, Pourfathi M, Rizi R, Hatefi A. Gadolinium-labeled affibody-XTEN recombinant vector for detection of HER2+ lesions of ovarian cancer lung metastasis using quantitative MRI. J Control Release. 2021;337:132-43. Epub 2021/07/21. doi: 10.1016/j.jconrel.2021.07.022. PubMed PMID: 34284047; PMCID: PMC8440463.
Pan Z, Du S, Wang K, Guo X, Mao Q, Feng X, Huang L, Wu S, Hou B, Chang YJ, Liu T, Chen T, Li H, Bachmann T, Bekker A, Hu H, Tao YX. Downregulation of a Dorsal Root Ganglion-Specifically Enriched Long Noncoding RNA is Required for Neuropathic Pain by Negatively Regulating RALY-Triggered Ehmt2 Expression. Adv Sci (Weinh). 2021;8(13):e2004515. Epub 2021/08/13. doi: 10.1002/advs.202004515. PubMed PMID: 34383386; PMCID: PMC8356248.
Rather GM, Pramono AA, Szekely Z, Bertino JR , Tedeschi PM. In cancer, all roads lead to NADPH. Pharmacol Ther. 2021;226:107864. Epub 2021/04/25. doi: 10.1016/j.pharmthera.2021.107864. PubMed PMID: 33894275.
Ren QN, Zhang H, Sun CY, Zhou YF, Yang XF, Long JW, Li XX, Mai SJ, Zhang MY, Zhang HZ, Mai HQ, Chen MS, Zheng XFS, Wang HY. Phosphorylation of Androgen Receptor by mTORC1 Promotes Liver Steatosis and Tumorigenesis. Hepatology. 2021. Epub 2021/08/27. doi: 10.1002/hep.32120. PubMed PMID: 34435708.
Shrirao AB, Schloss RS, Fritz Z, Shrirao MV, Rosen R, Yarmush ML. Autofluorescence of blood and its application in biomedical and clinical research. Biotechnol Bioeng. 2021;118(12):4550-76. Epub 2021/09/07. doi: 10.1002/bit.27933. PubMed PMID: 34487351.
Sillerud LO, Neuwelt AJ, Staquicini FI, Arap W, Pasqualini R. Repurposing Ferumoxytol as a Breast Cancer-Associated Macrophage Tracer with Five-Dimensional Quantitative [Fe]MRI of SPION Dynamics. Cancers (Basel). 2021;13(15). Epub 2021/08/08. doi: 10.3390/cancers13153802. PubMed PMID: 34359704; PMCID: PMC8345165.
Sinha G, Ferrer AI, Ayer S, El-Far MH, Pamarthi SH, Naaldijk Y, Barak P, Sandiford OA, Bibber BM, Yehia G, Greco SJ, Jiang JG, Bryan M, Kumar R, Ponzio NM, Etchegaray JP, Rameshwar P. Specific N-cadherin-dependent pathways drive human breast cancer dormancy in bone marrow. Life Sci Alliance. 2021;4(7). Epub 2021/06/04. doi: 10.26508/lsa.202000969. PubMed PMID: 34078741; PMCID: PMC8200294.
Sorrentino VG, Thota S, Gonzalez EA, Rameshwar P, Chang VT, Etchegaray JP. Hypomethylating Chemotherapeutic Agents as Therapy for Myelodysplastic Syndromes and Prevention of Acute Myeloid Leukemia. Pharmaceuticals (Basel). 2021;14(7). Epub 2021/08/07. doi: 10.3390/ph14070641. PubMed PMID: 34358067; PMCID: PMC8308509.
Staquicini DI, Tang FHF, Markosian C, Yao VJ, Staquicini FI, Dodero-Rojas E, Contessoto VG, Davis D, O'Brien P, Habib N, Smith TL, Bruiners N, Sidman RL, Gennaro ML, Lattime EC, Libutti SK, Whitford PC, Burley SK, Onuchic JN, Arap W, Pasqualini R. Design and proof of concept for targeted phage-based COVID-19 vaccination strategies with a streamlined cold-free supply chain. Proc Natl Acad Sci U S A. 2021;118(30). Epub 2021/07/09. doi: 10.1073/pnas.2105739118. PubMed PMID: 34234013; PMCID: PMC8325333.
Tang X, Dong Q, Li J, Li F, Michniak-Kohn BB, Zhao D, Ho CT, Huang Q. Anti-Melanogenic Mechanism of Tetrahydrocurcumin and Enhancing Its Topical Delivery Efficacy Using a Lecithin-Based Nanoemulsion. Pharmaceutics. 2021;13(8). Epub 2021/08/29. doi: 10.3390/pharmaceutics13081185. PubMed PMID: 34452146; PMCID: PMC8397971.
Wu A, Zhi J, Tian T, Cihan A, Cevher MA, Liu Z, David Y, Muir TW, Roeder RG, Yu M. DOT1L complex regulates transcriptional initiation in human erythroleukemic cells. Proc Natl Acad Sci U S A. 2021;118(27). Epub 2021/07/01. doi: 10.1073/pnas.2106148118. PubMed PMID: 34187895; PMCID: PMC8271641.
Yan J, Yan X, Hu S, Zhu H, Yan B. Comprehensive Interrogation on Acetylcholinesterase Inhibition by Ionic Liquids Using Machine Learning and Molecular Modeling. Environ Sci Technol. 2021;55(21):14720-31. Epub 2021/10/13. doi: 10.1021/acs.est.1c02960. PubMed PMID: 34636548.
Yu Y, Dong H, Peng Y, Welsh WJ. QSAR-Based Computational Approaches to Accelerate the Discovery of Sigma-2 Receptor (S2R) Ligands as Therapeutic Drugs. Molecules. 2021;26(17). Epub 2021/09/11. doi: 10.3390/molecules26175270. PubMed PMID: 34500703; PMCID: PMC8434483
|
|
Clinical Investigations &
Precision Therapeutics
|
|
Bruce G. Haffty, MD was awarded a Breast Cancer Research Foundation grant entitled "Novel Molecular Targets in Combination with Radiation Therapy in Breast Cancer Renewal 2021-2022". Term: 10/01/2021 - 09/30/2022. Total Annual Costs: $190,000.
Coral Omene, MD, PhD was awarded a Quantum Leap Healthcare Collaborative grant entitled "I-Spy 2 Trial: Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging and Molecular Analysis 2". Term: 08/10/2021 - 08/09/2031. Total Annual Costs: $11,500.
Coral Omene, MD, PhD was awarded a NJCCR grant entitled "Evaluating the Gene Rearrangement Landscape and Response to Neoadjuvant Chemotherapy in Triple Negative Breast Cancer and its Impact on Cancer Health Disparities". Term: 07/10/2021 - 06/30/2023. Total Annual Costs: $50,000.
Coral Omene, MD, PhD was presented with an American Association for Cancer award entitled "Minority and Minority-Serving Institution Faculty Scholar in Cancer Research Award" on 09/08/2021.
Lanjing Zhang, MD, MS, FCAP, FASCP was awarded a NSF grant entitled "Eager: Integration and Analysis of High-Dimensional Dataset". Term: 10/01/2021 - 09/30/2022. Total Annual Costs: $199,999.
Malcolm Mattes, MD was awarded a BMS Foundation grant entitled "Assessment of Early Radiation Oncology Involvement Alongside Standard Oncologic Care in the Management of Advanced/Metastatics Malignancies". Term: 10/01/2021 - 09/30/2023. Total Annual Costs: $120,000.
Martin J. Blaser, MD was awarded a NIAID grant entitled "Cohort and Biomarkers for COVID-19 Severity, Natural History, and Reinfection". Grant Number: 1R01AI158911-01A1. Term: 09/01/2021 - 08/31/2024. Total Annual Costs: $784,970.
Martin J. Blaser, MD was awarded a NJHF grant entitled "Effects of Exogenous Estrogen on the Murine Microbiome". Term: 07/01/2021 - 06/30/2022. Total Annual Costs: $10,000.
|
|
Coral Omene, MD, PhD presented “Association of body mass index with pathological complete response after neoadjuvant chemotherapy in a population-based cohort of Black breast cancer patients” at the 14th AACR Conference on The Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved held Oct 6 - 8, 2021 virtually.
Lanjing Zhang, MD, MS, FCAP, FASCP presented "AI-based prediction of cancer outcomes" at the 7th diagnostic course of Chinese American Pathologists Association held Sept 11, 2021 via Zoom.
Lanjing Zhang, MD, MS, FCAP, FASCP presented “Eosinophils in the gastrointestinal tract” at the Annal Meeting of the Singapore Division/Singaporean Society of Pathology, International Academy of Pathology held August 13, 2021 via Zoom.
|
|
Adams AM, Chick RC, Vreeland TJ, Clifton GT, Hale DF, McCarthy PM, O'Shea AE, Bohan PMK, Hickerson AT, Park H, Sloan AJ, Hyngstrom J, Berger AC, Jakub JW, Sussman JJ, Shaheen M, Wagner T, Faries MB, Peoples GE. Safety and efficacy of autologous tumor lysate particle-loaded dendritic cell vaccination in combination with systemic therapies in patients with recurrent and metastatic melanoma. Melanoma Res. 2021;31(4):378-88. Epub 2021/07/02. doi: 10.1097/CMR.0000000000000758. PubMed PMID: 34193804.
Alderuccio JP, Olszewski AJ, Evens AM, Collins GP, Danilov AV, Bower M, Jagadeesh D, Zhu C, Sperling A, Kim SH, Vaca R, Wei C, Sundaram S, Reddy N, Dalla Pria A, D'Angelo C, Farooq U, Bond DA, Berg S, Churnetski MC, Godara A, Khan N, Choi YK, Kassam S, Yazdy M, Rabinovich E, Post FA, Varma G, Karmali R, Burkart M, Martin P, Ren A, Chauhan A, Diefenbach C, Straker-Edwards A, Klein A, Blum KA, Boughan KM, Mian A, Haverkos BM, Orellana-Noia VM, Kenkre VP, Zayac A, Maliske SM, Epperla N, Caimi P, Smith SE, Kamdar M, Venugopal P, Feldman TA, Rector D, Smith SD, Stadnik A, Portell CA, Lin Y, Naik S, Montoto S, Lossos IS, Cwynarski K. HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysis. Blood Adv. 2021;5(14):2852-62. Epub 2021/07/21. doi: 10.1182/bloodadvances.2021004458. PubMed PMID: 34283175; PMCID: PMC8341354.
Bernstein AN, Talwar R, Handorf E, Syed K, Danella J, Ginzburg S, Belkoff L, Reese AC, Tomaszewski J, Trabulsi E, Singer EA, Jacobs B, Kutikov A, Uzzo R, Raman JD, Guzzo T, Smaldone MC, Correa A. Assessment of Prostate Cancer Treatment Among Black and White Patients During the COVID-19 Pandemic. JAMA Oncol. 2021;7(10):1467-73. Epub 2021/07/23. doi: 10.1001/jamaoncol.2021.2755. PubMed PMID: 34292311; PMCID: PMC8299356.
Castle PE, Einstein MH, Sahasrabuddhe VV. Cervical cancer prevention and control in women living with human immunodeficiency virus. CA Cancer J Clin. 2021;71(6):505-26. Epub 2021/09/10. doi: 10.3322/caac.21696. PubMed PMID: 34499351.
Chen H, Huang Y, Wang H, Shao Y, Yue NJ, Gu H, Duan Y, Feng A, Xu Z. Dosimetric comparison and biological evaluation of fixed-jaw intensity-modulated radiation therapy for T-shaped esophageal cancer. Radiat Oncol. 2021;16(1):158. Epub 2021/08/21. doi: 10.1186/s13014-021-01882-7. PubMed PMID: 34412656; PMCID: PMC8375041.
D'Angelo CR, Hanel W, Chen Y, Yu M, Yang D, Guo L, Karmali R, Burkart M, Ciccosanti C, David K, Risch Z, Murga-Zamalloa C, Devata S, Wilcox R, Savani M, Courville EL, Bachanova V, Rabinovich E, Peace D, Osman F, Epperla N, Kenkre VP. Impact of initial chemotherapy regimen on outcomes for patients with double-expressor lymphoma: A multi-center analysis. Hematol Oncol. 2021;39(4):473-82. Epub 2021/08/05. doi: 10.1002/hon.2902. PubMed PMID: 34347909.
Davis CH, Alexander HR, Jr. What is the Current Role of Hyperthermic Intraperitoneal Chemotherapy in Colorectal Cancer? Adv Surg. 2021;55:159-74. Epub 2021/08/15. doi: 10.1016/j.yasu.2021.05.012. PubMed PMID: 34389090.
Dias MP, Moser SC, Ganesan S, Jonkers J. Understanding and overcoming resistance to PARP inhibitors in cancer therapy. Nat Rev Clin Oncol. 2021;18(12):773-91. Epub 2021/07/22. doi: 10.1038/s41571-021-00532-x. PubMed PMID: 34285417.
Egan-Sherry D, Bhuta R, Cole PD, Gennarini LM, Kahn JM, Sulis ML, DeNardo BD, Welch JJG. Severe Vincristine-related Neurotoxicity in 5 Patients With Pediatric Acute Lymphoblastic Leukemia Requiring Discontinuation of Vincristine: A Description of Long-term Outcome. J Pediatr Hematol Oncol. 2021;43(7):e997-e9. Epub 2021/05/19. doi: 10.1097/MPH.0000000000002114. PubMed PMID: 34001785.
Eng C, Hochster H. Early-Onset Colorectal Cancer: The Mystery Remains. J Natl Cancer Inst. 2021. Epub 2021/08/19. doi: 10.1093/jnci/djab127. PubMed PMID: 34405226.
Feng CH, Disis ML, Cheng C, Zhang L. Multimetric feature selection for analyzing multicategory outcomes of colorectal cancer: random forest and multinomial logistic regression models. Lab Invest. 2021. Epub 2021/09/20. doi: 10.1038/s41374-021-00662-x. PubMed PMID: 34537824.
George MA, Qureshi S, Omene C, Toppmeyer DL, Ganesan S. Clinical and Pharmacologic Differences of CDK4/6 Inhibitors in Breast Cancer. Front Oncol. 2021;11:693104. Epub 2021/07/31. doi: 10.3389/fonc.2021.693104. PubMed PMID: 34327137; PMCID: PMC8313476.
Geynisman DM, Maranchie JK, Ball MW, Bratslavsky G, Singer EA. A 25 year perspective on the evolution and advances in an understanding of the biology, evaluation and treatment of kidney cancer. Urol Oncol. 2021;39(9):548-60. Epub 2021/06/08. doi: 10.1016/j.urolonc.2021.04.038. PubMed PMID: 34092483.
Gupta A, Jhawar SR, Sayan M, Yehia ZA, Haffty BG, Yu JB, Wang SY. Cost-Effectiveness of Adjuvant Treatment for Ductal Carcinoma In Situ. J Clin Oncol. 2021;39(21):2386-96. Epub 2021/05/22. doi: 10.1200/JCO.21.00831. PubMed PMID: 34019456.
Hathout L, Wang Y, Wang Q, Vergalasova I, Elshaikh MA, Dimitrova I, Damast S, Li JY, Fields EC, Beriwal S, Keller A, Kidd EA, Usoz M, Jolly S, Jaworski E, Leung EW, Donovan E, Taunk NK, Chino J, Natesan D, Russo AL, Lea JS, Albuquerque KV, Lee LJ. A Multi-Institutional Analysis of Adjuvant Chemotherapy and Radiation Sequence in Women With Stage IIIC Endometrial Cancer. Int J Radiat Oncol Biol Phys. 2021;110(5):1423-31. Epub 2021/03/08. doi: 10.1016/j.ijrobp.2021.02.055. PubMed PMID: 33677053.
Hochster HS. The Unhappy Intersection of Cancer and COVID-19. Oncology (Williston Park). 2021;35(8):459. Epub 2021/08/17. doi: 10.46883/ONC.2021.3508.0459. PubMed PMID: 34398589.
Hsieh K, Housri N, Haffty BG, Smith B, Burt LM. Radiation Oncologists' Views on Breast Radiation Therapy Guidelines: Utilizing an Online Q&A Platform to Assess Current Views on Whole-Breast Irradiation Therapy. Clin Breast Cancer. 2021;21(5):408-16. Epub 2021/04/06. doi: 10.1016/j.clbc.2021.02.010. PubMed PMID: 33814285.
Johnson S, Ziegler J, August DA. Timing of oral intake after esophagectomy: A narrative review of the literature and case report. Nutr Clin Pract. 2021. Epub 2021/10/06. doi: 10.1002/ncp.10777. PubMed PMID: 34608676.
Johnson S, Ziegler J, August DA. Cannabinoid use for appetite stimulation and weight gain in cancer care: Does recent evidence support an update of the European Society for Clinical Nutrition and Metabolism clinical guidelines? Nutr Clin Pract. 2021;36(4):793-807. Epub 2021/03/06. doi: 10.1002/ncp.10639. PubMed PMID: 33666957.
Kahn JM, Yang JC, Yahalom J, Dabaja BS, Vapiwala N, Hoppe BS, Tseng YD, Pinnix CC, Parikh RR, Sim AJ, Plastaras JP, Gunther JR, with the Ilrog Educational Steering Committee AEC. Assessment of Lymphoma and Other Hematologic Malignancies Training Needs Among Radiation Oncology Residents: a Brief Report. J Cancer Educ. 2021. Epub 2021/10/04. doi: 10.1007/s13187-021-02098-9. PubMed PMID: 34601699; PMCID: PMC8487329.
Kangas-Dick A, Berger AC, Koshenkov V. ASO Author Reflections: Gene Expression Profiling for Melanoma: Is it Ready for Prime Time? Ann Surg Oncol. 2021;28(8):4590-1. Epub 2021/01/23. doi: 10.1245/s10434-021-09599-3. PubMed PMID: 33479864.
Kangas-Dick AW, Greenbaum A, Gall V, Groisberg R, Mehnert J, Chen C, Moore DF, Berger AC, Koshenkov V. Evaluation of a Gene Expression Profiling Assay in Primary Cutaneous Melanoma. Ann Surg Oncol. 2021;28(8):4582-9. Epub 2021/01/25. doi: 10.1245/s10434-020-09563-7. PubMed PMID: 33486642.
Khullar K, Plascak JJ, Parikh RR. Acute lymphoblastic leukemia (ALL) in adults: disparities in treatment intervention based on access to treatment facility. Leuk Lymphoma. 2021:1-9. Epub 2021/09/09. doi: 10.1080/10428194.2021.1975187. PubMed PMID: 34493143.
Kumar AJ, Nelson J, Rodday AM, Evens AM, Friedberg JW, Wildes TM, Parsons SK. Development and validation of a prediction model for 1-year mortality among older adults with Hodgkin Lymphoma who receive dose-intense chemotherapy. J Geriatr Oncol. 2021;12(8):1233-9. Epub 2021/08/01. doi: 10.1016/j.jgo.2021.07.003. PubMed PMID: 34330667; PMCID: PMC8557127.
Lee SF, Evens AM, Ng AK, Luque-Fernandez MA. Socioeconomic inequalities in treatment and relative survival among patients with diffuse large B-cell lymphoma: a Hong Kong population-based study. Sci Rep. 2021;11(1):17950. Epub 2021/09/11. doi: 10.1038/s41598-021-97455-5. PubMed PMID: 34504223; PMCID: PMC8429768.
Li H, Bera K, Toro P, Fu P, Zhang Z, Lu C, Feldman M, Ganesan S, Goldstein LJ, Davidson NE, Glasgow A, Harbhajanka A, Gilmore H, Madabhushi A. Collagen fiber orientation disorder from H&E images is prognostic for early stage breast cancer: clinical trial validation. NPJ Breast Cancer. 2021;7(1):104. Epub 2021/08/08. doi: 10.1038/s41523-021-00310-z. PubMed PMID: 34362928; PMCID: PMC8346522.
Moerdler S, Gampel B, Levine JM, Chou A, Madhusoodhan P, Oberg JA, Pierro J, Roberts SS, Satwani P. COVID-19 has changed the way we think about training future pediatric hematologists/oncologists. Pediatr Blood Cancer. 2021;68(8):e29088. Epub 2021/04/30. doi: 10.1002/pbc.29088. PubMed PMID: 33913620; PMCID: PMC8209867.
Mondal A, NeMoyer R, Vora M, Napoli L, Syed Z, Langenfeld J, Jia D, Peng Y, Gilleran J, Roberge J, Rongo C, Jabbour SK, Langenfeld J. Bone morphogenetic protein receptor 2 inhibition destabilizes microtubules promoting the activation of lysosomes and cell death of lung cancer cells. Cell Commun Signal. 2021;19(1):97. Epub 2021/09/27. doi: 10.1186/s12964-021-00743-w. PubMed PMID: 34563224; PMCID: PMC8466694.
Mutter RW, Choi JI, Jimenez RB, Kirova YM, Fagundes M, Haffty BG, Amos RA, Bradley JA, Chen PY, Ding X, Carr AM, Taylor LM, Pankuch M, Vega RBM, Ho AY, Nystrom PW, McGee LA, Urbanic JJ, Cahlon O, Maduro JH, MacDonald SM. Proton Therapy for Breast Cancer: A Consensus Statement From the Particle Therapy Cooperative Group Breast Cancer Subcommittee. Int J Radiat Oncol Biol Phys. 2021;111(2):337-59. Epub 2021/05/29. doi: 10.1016/j.ijrobp.2021.05.110. PubMed PMID: 34048815; PMCID: PMC8416711.
Neibart SS, Portal DE, Malhotra J, Jabbour SK, Roy JA, Strom BL. Validation of a claims-based algorithm for identifying non-infectious pneumonitis in patients diagnosed with lung cancer. Pharmacoepidemiol Drug Saf. 2021;30(12):1624-9. Epub 2021/08/12. doi: 10.1002/pds.5339. PubMed PMID: 34378828; PMCID: PMC8578340.
Olszewski A, Kurt H, Evens AM. Defining and Treating High-grade B-cell lymphoma, NOS. Blood. 2021. Epub 2021/09/16. doi: 10.1182/blood.2020008374. PubMed PMID: 34525177.
Pamarthy S, Sabaawy HE. Patient derived organoids in prostate cancer: improving therapeutic efficacy in precision medicine. Mol Cancer. 2021;20(1):125. Epub 2021/10/01. doi: 10.1186/s12943-021-01426-3. PubMed PMID: 34587953; PMCID: PMC8480086.
Panda A, Ganesan S. Genomic and Immunologic Correlates of Indoleamine 2,3-Dioxygenase Pathway Expression in Cancer. Front Genet. 2021;12:706435. Epub 2021/08/10. doi: 10.3389/fgene.2021.706435. PubMed PMID: 34367262; PMCID: PMC8340027.
Prabhu V, Kathe N, Saxena K, Walia A, Markan R, Myers E, Einstein M. Incremental healthcare resource utilization and costs for patients with cervical, vaginal, vulvar, anal, and oropharyngeal cancer in the United States. Curr Med Res Opin. 2021;37(9):1599-607. Epub 2021/05/22. doi: 10.1080/03007995.2021.1932447. PubMed PMID: 34018457.
Psutka SP, Singer EA, Gore J. A 25-year perspective on advances in the study of the epidemiology, disparities, and outcomes of urologic cancers. Urol Oncol. 2021;39(9):595-601. Epub 2021/05/04. doi: 10.1016/j.urolonc.2021.03.019. PubMed PMID: 33934967.
Qian X, Zhang W, Yang H, Zhang L, Kang N, Lai J. Role of Yes-associated Protein-1 in Gastrointestinal Cancers and Hepatocellular Carcinoma. Explor Res Hypothesis Med. 2021;6(3):110-7. Epub 2021/10/01. doi: 10.14218/ERHM.2021.00017. PubMed PMID: 34589656; PMCID: PMC8478289.
Qu H, Zhou M, Yan Z, Wang H, Rustgi VK, Zhang S, Gevaert O, Metaxas DN. Genetic mutation and biological pathway prediction based on whole slide images in breast carcinoma using deep learning. NPJ Precis Oncol. 2021;5(1):87. Epub 2021/09/25. doi: 10.1038/s41698-021-00225-9. PubMed PMID: 34556802; PMCID: PMC8460699.
Savage B, Cole PD, Lin H. Racial and Economic Differences in the Risk of Hyperglycemia in Children Hospitalized With Acute Lymphoblastic Leukemia. J Pediatr Oncol Nurs. 2021;38(5):277-84. Epub 2021/05/06. doi: 10.1177/10434542211011040. PubMed PMID: 33949234.
Zhang Y, Jabbour SK, Zhang A, Liu B, Yue NJ, Biswal NC. Proton beam therapy can achieve lower vertebral bone marrow dose than photon beam therapy during chemoradiation therapy of esophageal cancer. Med Dosim. 2021;46(3):229-35. Epub 2021/01/18. doi: 10.1016/j.meddos.2020.12.003. PubMed PMID: 33454170.
|
|
Genomic Instability & Cancer Genetics |
|
Rutgers Cancer Institute of New Jersey Receives an $11.5 Million NCI Program Project Grant (P01) to Study Genomic Instability in Cancer Development and Treatment |
|
The National Cancer Institute (NCI) has awarded a five-year $11.5 million Program Project Grant (P01) to Rutgers Cancer Institute of New Jersey to support multi-disciplinary research on the mechanisms of BRCA networks underlying tumorigenesis and therapeutic response.
The BRCA network of genes, including BRCA1, PALB2, BRCA2, and many associated genes, are critical to ensure the genomic stability during cell division. Functional alterations of this gene network not only contribute to the development of a major subset of human cancers, but also render the affected cancers responsive to unique therapeutic approaches. Zhiyuan Shen, MD, PhD, a co-leader of the Genomic Instability and Cancer Genetics program at CINJ, will lead a team of co-investigators, including Drs. Shridar Ganesan, MD, PhD, Bing Xia, PhD, Samuel F. Bunting, MBiochem, PhD, and Subhajyoti De, PhD, to conduct four synergistic research projects with the support of two shared resource cores. The overall objectives of this P01 are to understand the mechanisms by which the BRCA network of genes maintain genomic integrity and suppress tumorigenesis, and to exploit the mechanistic understanding for new opportunities in cancer therapy.
|
|
Advaitha Madireddy, PhD was awarded a DoD grant entitled "Understanding the Mechanisms Driving Clonal Hematopoiesis-Associated Mutations". Term: 09/15/2021 - 09/14/2024. Total Annual Costs: $261,666.
Antonina Mitrofanova, PhD was awarded a ACS grant entitled "Systems Analysis of Drug Resistance in Prostate Cancer". Term: 07/01/2021 - 06/30/2025. Total Annual Costs: $198,000.
Bing Xia, PhD was awarded a NCI grant entitled "Regulation of DNA Replication Kinetics by BRCA2 After DNA Damage". Grant Number: 1R01CA262227-01. Term: 07/01/2021 - 06/30/2026. Total Annual Costs: $344,772.
Chang S. Chan, PhD was awarded a NJ ACTS grant entitled "Development of Computational Methods to Identify Oncogenic Tyrosine Kinase Transcripts". Term: 10/08/2021 - 10/07/2022. Total Annual Costs: $50,000.
Jay A. Tischfield, PhD, FFACMG was awarded a NJCTS grant entitled "Center for Excellence for Tourette Syndrome & Associated Disorders Genetics Repository". Term: 07/01/2021 - 06/30/2022. Total Annual Costs: $50,000.
Michael P. Verzi, PhD was awarded a NIDDK grant entitled "Mechanisms Driving Metabolic Shifts in the Intestinal Epithelium". Grant Number: 1R01DK126446-01A1. Term: 09/23/2021 - 05/31/2026. Total Annual Costs: $419,526.
Sabine Petry, PhD was awarded The Pew Innovation Fund Award from The Pew Charitable Trusts. Term: 07/01/2021 - 06/30/2023. Total Annual Costs: $100,000.
Sabine Petry, PhD and Zhiyuan Shen, MD, PhD were awarded a NJ ACTS grant entitled "Targeting of Mitotic Spindle Assembly Factor TPX2 for Cancer Therapy (NJ ACTS Pilot Award)". Term: 10/13/2021 - 10/12/2022. Total Annual Costs: $55,000 each.
Zhaohui Feng, PhD was awarded a National Cancer Institute (NCI) R01 CA229257 Grant, entitled “The regulation of mutant p53 protein accumulation in cancer: molecular basis and therapeutic potential”. Term: 07/01/2021-6/30/2026. Total Award Amount: $2,086,492.
Zhiyuan Shen, MD, PhD was awarded with the Basic Sciences Research Award presented by the RBHS Chancellor Awards in November 2021.
Zhiyuan Shen, MD, PhD was awarded a NCI grant entitled "Molecular modulators of radiation-induced chromosome instability and hematopoietic damage" Grant Number: 2R01CA195612-06A1 Term: 07/01/2021 - 06/30/2026. Total Award Amount: $1,876,495.
|
|
Devlin L, Okletey J, Perkins G, Bowen JR, Nakos K, Montagna C, Spiliotis ET. Proteomic profiling of the oncogenic septin 9 reveals isoform-specific interactions in breast cancer cells. Proteomics. 2021;21(19):e2100155. Epub 2021/08/20. doi: 10.1002/pmic.202100155. PubMed PMID: 34409731; PMCID: PMC8612247.
Hu W, Feng Z. Hypothermia Is a Potential New Therapy for a Subset of Tumors with Mutant p53. Cancer Res. 2021;81(14):3762-3. Epub 2021/07/17. doi: 10.1158/0008-5472.CAN-21-1025. PubMed PMID: 34266914.
Hussein S, Khanna P, Yunus N, Gatza ML. Nuclear Receptor-Mediated Metabolic Reprogramming and the Impact on HR+ Breast Cancer. Cancers (Basel). 2021;13(19). Epub 2021/10/14. doi: 10.3390/cancers13194808. PubMed PMID: 34638293; PMCID: PMC8508306.
Kang Z, Fu P, Alcivar AL, Fu H, Redon C, Foo TK, Zuo Y, Ye C, Baxley R, Madireddy A, Buisson R, Bielinsky AK, Zou L, Shen Z, Aladjem MI, Xia B. BRCA2 associates with MCM10 to suppress PRIMPOL-mediated repriming and single-stranded gap formation after DNA damage. Nat Commun. 2021;12(1):5966. Epub 2021/10/15. doi: 10.1038/s41467-021-26227-6. PubMed PMID: 34645815; PMCID: PMC8514439.
Kwon M, Rubio G, Nolan N, Auteri P, Volmar JA, Adem A, Javidian P, Zhou Z, Verzi MP, Pine SR, Libutti SK. FILIP1L Loss Is a Driver of Aggressive Mucinous Colorectal Adenocarcinoma and Mediates Cytokinesis Defects through PFDN1. Cancer Res. 2021;81(21):5523-39. Epub 2021/08/22. doi: 10.1158/0008-5472.CAN-21-0897. PubMed PMID: 34417201; PMCID: PMC8563430.
Liu J, Zhang C, Wang X, Hu W, Feng Z. Tumor suppressor p53 cross-talks with TRIM family proteins. Genes Dis. 2021;8(4):463-74. Epub 2021/06/29. doi: 10.1016/j.gendis.2020.07.003. PubMed PMID: 34179310; PMCID: PMC8209353.
Sabaawy HE, Ryan BM, Khiabanian H, Pine SR. JAK/STAT of all trades: Linking inflammation with cancer development, tumor progression, and therapy resistance. Carcinogenesis. 2021. Epub 2021/08/21. doi: 10.1093/carcin/bgab075. PubMed PMID: 34415330.
Satas G, Zaccaria S, El-Kebir M, Raphael BJ. DeCiFering the elusive cancer cell fraction in tumor heterogeneity and evolution. Cell Syst. 2021;12(10):1004-18 e10. Epub 2021/08/21. doi: 10.1016/j.cels.2021.07.006. PubMed PMID: 34416171; PMCID: PMC8542635.
Sun H, Cao S, Mashl RJ, Mo CK, Zaccaria S, Wendl MC, Davies SR, Bailey MH, Primeau TM, Hoog J, Mudd JL, Dean DA, 2nd, Patidar R, Chen L, Wyczalkowski MA, Jayasinghe RG, Rodrigues FM, Terekhanova NV, Li Y, Lim KH, Wang-Gillam A, Van Tine BA, Ma CX, Aft R, Fuh KC, Schwarz JK, Zevallos JP, Puram SV, Dipersio JF, Consortium NCIP, Davis-Dusenbery B, Ellis MJ, Lewis MT, Davies MA, Herlyn M, Fang B, Roth JA, Welm AL, Welm BE, Meric-Bernstam F, Chen F, Fields RC, Li S, Govindan R, Doroshow JH, Moscow JA, Evrard YA, Chuang JH, Raphael BJ, Ding L. Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidatesfor targeted treatment. Nat Commun. 2021;12(1):5086. Epub 2021/08/26. doi: 10.1038/s41467-021-25177-3. PubMed PMID: 34429404; PMCID: PMC8384880.
Tong K, Kothari OA, Haro KS, Panda A, Bandari MM, Carrick JN, Hur JJ, Zhang L, Chan CS, Xing J, Gatza ML, Ganesan S, Verzi MP. SMAD4 is critical in suppression of BRAF-V600E serrated tumorigenesis. Oncogene. 2021;40(41):6034-48. Epub 2021/08/29. doi: 10.1038/s41388-021-01997-x. PubMed PMID: 34453124; PMCID: PMC8559887.
|
|
Basic Research & Clinical Research Programs
Rutgers Cancer Institute of New Jersey
|
|
|
|
|
|
|
